Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAINTAIN: Ribociclib After Progression on CDK4/6 Inhibition
NCT02632045Phase 2Completed
- Sponsor
- Melissa K. Accordino
- Start
- Mar 2016
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Hormone-Receptor-Positive Breast Cancer comparing Ribociclib + Fulvestrant with Placebo + Fulvestrant (2 arms). Primary endpoint: Progression-Free Survival at 30 months. Started Mar 2016; status: completed.
02
Drugs
ribociclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT02632045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632045.